Log in

Relevant bibliographies by topics / Antiresorptive Therapy / Journal articles

To see the other types of publications on this topic, follow the link: Antiresorptive Therapy.

Journal articles on the topic 'Antiresorptive Therapy'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Antiresorptive Therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Pande, Ira, and David J. Hosking. "Oral antiresorptive therapy." Current Osteoporosis Reports 2, no. 4 (2004): 116–22. http://dx.doi.org/10.1007/s11914-996-0010-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Pande, Ira, and David J. Hosking. "Oral antiresorptive therapy." Current Osteoporosis Reports 2, no. 4 (2004): 116–22. http://dx.doi.org/10.1007/bf02686924.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Pande, Ira, and David J. Hosking. "Oral antiresorptive therapy." Current Rheumatology Reports 7, no. 1 (2005): 71–77. http://dx.doi.org/10.1007/s11926-005-0012-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Dziewulska, Aleksandra, Weronika Kiełt, Julia Kozłowska, et al. "Implications in dental treatment during the use of antiresorptive drugs - a literature review." Journal of Education, Health and Sport 69 (October 3, 2024): 55356. http://dx.doi.org/10.12775/jehs.2024.69.55356.

Full text

Abstract:

Introduction: Antiresorptive drugs such as bisphosphonates and denosumab are crucial for treating osteoporosis, metastatic bone disease, and hypercalcemia by inhibiting osteoclast function. They can lead to medication-related osteonecrosis of the jaw (MRONJ) following invasive dental procedures, requiring careful management to mitigate potential adverse effects. Purpose of work: Synthesis of knowledge about the impact of taking antiresorptive drugs on aspects of dental treatment. Materials and methods: Materials used in this study were found in the PubMed and Google Scholar database, using the

APA, Harvard, Vancouver, ISO, and other styles

5

McClung, M. R. "28. Combination Antiresorptive Therapy." Menopause 5, no. 4 (1998): 244. http://dx.doi.org/10.1097/00042192-199805040-00037.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Bruckmoser, Emanuel, Miriam Palaoro, Lukas Latzko, Dagmar Schnabl, Sabrina B. Neururer, and Johannes Laimer. "Choosing the Right Partner for Medication Related Osteonecrosis of the Jaw: What Central European Dentists Know." International Journal of Environmental Research and Public Health 18, no. 9 (2021): 4466. http://dx.doi.org/10.3390/ijerph18094466.

Full text

Abstract:

Medication-related osteonecrosis of the jaw (MRONJ) is a side effect of antiresorptive drugs. In this online survey, the awareness and knowledge of dentists regarding MRONJ was evaluated, and potential implications for oncologists are discussed. Questionnaires were emailed to dentists from Germany, Austria, Switzerland, and South Tyrol to evaluate disease-related knowledge and management. In addition to the overall score, a separate score was calculated for knowledge (maximum score: 15 points) and management (maximum score: 6 points) questions, and 1197 valid replies with completed questionnai

APA, Harvard, Vancouver, ISO, and other styles

7

BOSCHERT, SHERRY. "Encouragement Aids Antiresorptive Therapy Adherence." Family Practice News 41, no. 16 (2011): 36. http://dx.doi.org/10.1016/s0300-7073(11)70861-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Boskovic, Ksenija. "Indications for initiation of drug therapy and modern therapy protocols in patients with osteoporosis." Medical review 75, Suppl. 2 (2022): 7–12. http://dx.doi.org/10.2298/mpns22s2007b.

Full text

Abstract:

Introduction. Pharmacotherapy and physical therapy in patients with osteoporosis are aimed at increasing bone density and reducing the risk of fall in order to prevent fractures. Medications approved for the treatment of osteoporosis reduce the risk of fracture, either by reducing bone resorption or by stimulating bone formation. Bisphosphonates are most widely used antiresorptive agents that lower bone turnover markers to premenopausal levels and reduce fracture rates. Bisphosphonates bind to bone minerals and have a long-lasting effect. Long-term, continuous use of oral bisphosphonates is us

APA, Harvard, Vancouver, ISO, and other styles

9

Pimolbutr, Kununya, Stephen Porter, and Stefano Fedele. "Osteonecrosis of the Jaw Associated with Antiangiogenics in Antiresorptive-Naïve Patient: A Comprehensive Review of the Literature." BioMed Research International 2018 (2018): 1–14. http://dx.doi.org/10.1155/2018/8071579.

Full text

Abstract:

Objectives. To review the available literature on medication-related osteonecrosis of the jaw (MRONJ) associated with antiangiogenics in antiresorptive-naïve individuals. Methods. A literature search was performed using MEDLINE via PubMed, EMBASE, and Web of Science in December 2017. Results. We identified reports describing a total of 35 antiresorptive drugs-naïve patients who developed antiangiogenic-related MRONJ. The mean age of these patients was 59.06 years and the F : M ratio was 4 : 5. The most common underlying disease was metastatic renal cell cancer. Pain to the mandible was the mos

APA, Harvard, Vancouver, ISO, and other styles

10

Rizzoli, René. "Combined and sequential therapies with anabolic and antiresorptive drugs in the management of patients with postmenopausal osteoporosis." International Journal of Bone Fragility 3, no. 1 (2023): 7–15. http://dx.doi.org/10.57582/ijbf.230301.007.

Full text

Abstract:

The aim of osteoporosis therapy is to reduce the increased fracture risk associated with osteoporosis-related bone fragility. Prevention of fragility fracture relies on balanced nutrition, weight-bearing and balance-improving physical exercises, and pharmacological therapies. Among the latter, the antiresorptive drugs are the most widely used. Bone formation stimulators (anabolics) are second line-therapy with reversible effects once discontinued. For patients at very high risk or imminent risk of fracture, the question arises of whether combining drugs with different modes of action, or using

APA, Harvard, Vancouver, ISO, and other styles

11

Miller, Paul D. "The Treatment of Osteoporosis: Antiresorptive Therapy." Clinics in Laboratory Medicine 20, no. 3 (2000): 603–22. http://dx.doi.org/10.1016/s0272-2712(18)30056-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Noemi, Picardo. "Dental management in Oncology patient: osteonecrosis related osteonecrosis of the Jaw (MRONJ)." International Journal of Clinical Case Reports and Reviews 4, no. 1 (2020): 01–02. http://dx.doi.org/10.31579/2690-4861/058.

Full text

Abstract:

It is essential that oncological patients treated with antiresorptives or antiangiogenic drugs diagnosed Medication Related Osteonecrosis of the Jaw (MRONJ) must be treated in an interdisciplinary fashion. The patient’s stomatognathic system should be examined preventatively prior to the initiation of antiresorptive drugs in order to avoid pathological buccal manifestations, following the same healthcare clinical protocols used for patients receiving head and neck radiotherapy. Additionally, patients should be informed of the precautions to be taken, including regular dental appointments for o

APA, Harvard, Vancouver, ISO, and other styles

13

Synnott, Pádraig, Michelle Brennan, Shaun O'Keeffe, and Michelle Canavan. "279 Quality Improvement Audit on Bone Health Assessment and Secondary Prevention of Patients Discharged from an In-patient Rehabilitation Unit Post Fracture." Age and Ageing 48, Supplement_3 (2019): iii17—iii65. http://dx.doi.org/10.1093/ageing/afz103.175.

Full text

Abstract:

Abstract Background Osteoporosis accounts for more disability-adjusted life years than many non-communicable diseases. Identification and treatment is important to reduce morbidity and mortality associated with further fracture.(1) National Osteoporosis Guideline Group recommends all patients with a fragility fracture should undergo a bone health assessment and commence pharmacological therapy if indicated.(2) Methods Electronic discharge summaries of all patients with a diagnosis of fracture discharged from an off-site rehabilitation unit from 1st January 2018 to 31st December 2018 were revie

APA, Harvard, Vancouver, ISO, and other styles

14

Laimer, Johannes, Martin Hechenberger, Daniela Müller, et al. "Dental pathologies in tumor patients with bone metastases or multiple myeloma scheduled for antiresorptive therapy." Future Oncology 17, no. 21 (2021): 2705–11. http://dx.doi.org/10.2217/fon-2020-1240.

Full text

Abstract:

Background: Medication-related osteonecrosis of the jaw (MRONJ) is a potentially severe complication of mainly antiresorptive drugs. We evaluated the frequency of dentoalveolar pathologies in patients scheduled for antiresorptive therapy in a ‘real-world’ setting, also including patients with poor oral health potentially requiring tooth extractions and/or other dentoalveolar surgery. This approach is in contrast to the setting of recent randomized trials with restrictive exclusion criteria. Patients & methods: We prospectively included patients suffering from solid tumors with osseous meta

APA, Harvard, Vancouver, ISO, and other styles

15

Guazzo, Riccardo, Luca Sbricoli, Sara Ricci, Eriberto Bressan, Adriano Piattelli, and Flavia Iaculli. "Medication-Related Osteonecrosis of the Jaw and Dental Implants Failures: A Systematic Review." Journal of Oral Implantology 43, no. 1 (2017): 51–57. http://dx.doi.org/10.1563/aaid-joi-16-00057.

Full text

Abstract:

No well-established evidence supporting safe use of bisphosphonates (BPs) or other antiresorptive agents prior, during, or after dentoalveolar surgery, are currently available; moreover, the real risk of osteonecrosis of the jaw (ONJ) development is still unknown. The aim of the present systematic review was to assess the scientific literature concerning the implants placement in antiresorptive agent users and the related risk of implants failure and ONJ development. English papers published from January 2003 until December 2014 were identified on the MEDLINE database. Titles and abstracts ret

APA, Harvard, Vancouver, ISO, and other styles

16

Zhang, Jie, Kenneth G. Saag, and Jeffrey R. Curtis. "Long-term Safety Concerns of Antiresorptive Therapy." Rheumatic Disease Clinics of North America 37, no. 3 (2011): 387–400. http://dx.doi.org/10.1016/j.rdc.2011.08.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Cusano, Natalie E., and John P. Bilezikian. "Combination Anabolic and Antiresorptive Therapy for Osteoporosis." Endocrinology and Metabolism Clinics of North America 41, no. 3 (2012): 643–54. http://dx.doi.org/10.1016/j.ecl.2012.04.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Deal, Chad. "Combination Therapy With Anabolic and Antiresorptive Agents." Clinical Reviews in Bone and Mineral Metabolism 4, no. 4 (2006): 291–304. http://dx.doi.org/10.1385/bmm:4:4:291.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Sindel, Dilşad. "Osteoporosis: Spotlight on current approaches to pharmacological treatment." Turkish Journal of Physical Medicine and Rehabilitation 69, no. 2 (2023): 140–52. http://dx.doi.org/10.5606/tftrd.2023.13054.

Full text

Abstract:

Despite the availability of safe and effective anti-osteoporosis treatments, osteoporosis continues to be undertreated. The increase in fragility fractures, which is the main clinical consequence of osteoporosis, is a major problem for healthcare systems of countries. A broad range of drugs including antiresorptive and anabolic agents are used in the pharmacological treatment of osteoporosis. Fracture risk assessment in drug selection is of utmost importance in terms of guiding treatment. The recommended thresholds for osteoporosis treatment decision making are based on major osteoporotic and

APA, Harvard, Vancouver, ISO, and other styles

20

Gremke, Niklas, Sebastian Griewing, Arturas Kadys, Karel Kostev, Uwe Wagner, and Matthias Kalder. "Initiation of Antiresorptive Drug Treatment during Endocrine Therapy for Breast Cancer—A Retrospective Cohort Study of 161,492 Patients in Germany." Cancers 15, no. 6 (2023): 1847. http://dx.doi.org/10.3390/cancers15061847.

Full text

Abstract:

Background: The aim of this retrospective cohort study was to measure the proportion of women with an initial prescription of an antiresorptive drug (bisphosphonates or denosumab) during five years of endocrine breast cancer therapy. Methods: The study included women with an initial prescription of tamoxifen (TAM) or aromatase inhibitors (AIs) between January 2016 and December 2020. Kaplan–Meier analyses were performed to show the cumulative incidence of antiresorptive drug prescription for TAM and AIs separately for four age groups. A univariable Cox proportional hazards regression model was

APA, Harvard, Vancouver, ISO, and other styles

21

Cusano, Natalie E., Aline G. Costa, Barbara C. Silva, and John P. Bilezikian. "Therapy of Osteoporosis in Men with Teriparatide." Journal of Osteoporosis 2011 (2011): 1–7. http://dx.doi.org/10.4061/2011/463675.

Full text

Abstract:

Osteoanabolic therapy is an attractive therapeutic option for men with osteoporosis because it directly stimulates bone formation, an action not shared by any antiresorptive drug. Teriparatide (recombinant human PTH(1-34)) and PTH(1-84) are available in many countries but PTH(1-84) is not available in the United States. Only teriparatide is approved for the treatment of osteoporosis in men. It is also indicated in glucocorticoid-induced osteoporosis. Teriparatide is associated with major gains in bone density at the lumbar spine and, to a lesser extent, in the hip regions. Vertebral and nonver

APA, Harvard, Vancouver, ISO, and other styles

22

Zurányi, Anna, Enikő Vasziné Szabó, and Zsuzsanna Tóth. "A gyógyszer által indukált állcsontnecrosis-kockázat mértékének meghatározása az általános fogorvosi gyakorlatban." Orvosi Hetilap 160, no. 7 (2019): 243–51. http://dx.doi.org/10.1556/650.2019.31204.

Full text

Abstract:

Abstract: Medication-related osteonecrosis of the jaw may appear as adverse effect in antiresorptive therapy. Its successful treatment is challenging. We aimed to gather the systemic and local factors playing a role in etiology, published after its recognition. Risk factors were collected from the PubMed database 1998–2018. The three main groups of risk patients are: patients starting, patients having antiresorptive therapy, osteonecrosis diagnosed patients. The dentist must recognize risk factors, determine appropriate treatment plan and frequency of check-ups. Oncological disease treated int

APA, Harvard, Vancouver, ISO, and other styles

23

Anjum, Sidrah, Attya Bhatti, Fahd Qadir, Usman Ashraf, and Peter John. "RANKL Signaling Pathway: A Potential Target for Antiresorptive Therapy in Rheumatoid Arthritis." NUST Journal of Natural Sciences 3, no. 1 (2021): 35–52. http://dx.doi.org/10.53992/njns.v3i1.20.

Full text

Abstract:

Rheumatoid arthritis (RA) is a chronic polyarthritic autoimmune condition characterized by severe bone erosion. Osteoclasts, the bone resorbing cells, Rheumatoid arthritis (RA) is a chronic polyarthritic autoimmune condition characterized by severe bone erosion. Osteoclasts, the bone resorbing cells, are overly produced from the synovial inflammatory tissues in RA leading to excessive bone loss. RANKL-signaling pathway has been established to be the major pathway involved in osteoclastogenesis. This review highlights the role of around 40 osteoclastogenic factors involved in RANKL signaling an

APA, Harvard, Vancouver, ISO, and other styles

24

Piple, Amit, Christian Taylor Smith, David W. Barton, and Jonathan J. Carmouche. "Proximal Humerus Fractures in the Geriatric Population Present an Opportunity to Improve Recognition and Treatment of Osteoporosis." Geriatric Orthopaedic Surgery & Rehabilitation 11 (January 1, 2020): 215145932093510. http://dx.doi.org/10.1177/2151459320935103.

Full text

Abstract:

Introduction: Osteoporosis remains an undertreated disease entity causing substantial morbidity and mortality. Proximal humerus fractures are a common sentinel fracture, providing an opportunity to intervene with antiresorptive therapy before more subsequent fractures occur. Despite the success of programs aimed to improve postfracture osteoporosis recognition and management, less than 30% of patients presenting with a fragility fracture are diagnosed or treated for osteoporosis nationally. Further elucidation of diagnosis and management of osteoporosis following humerus fracture is warranted.

APA, Harvard, Vancouver, ISO, and other styles

25

Kim, Hyo-Jung, Min-Keun Kim, and Young-Wook Park. "Impact of antiresorptive drugs on dental implant success rate: A systematic review." Journal of Korean Dental Association 63, no. 5 (2025): 153–61. https://doi.org/10.22974/jkda.2025.63.5.002.

Full text

Abstract:

Purpose: This systematic review aimed to evaluate the impact of antiresorptive drugs on dental implant success rate, and to suggest guidelines for dental implant placement in patients under antiresorptive therapies.Materials and Methods: An electrical search was conducted in databases such as PubMed and Cochrane, followed by Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) guidelines. the review included studies from 2014 march, focusing on various study designs like randomized control studies, cohort studies, and case series.Results: In a total of 196 articles, base

APA, Harvard, Vancouver, ISO, and other styles

26

Rato, M., F. Oliveira Pinheiro, S. Garcia, et al. "POS1113 ANTIRESORPTIVE THERAPY AFTER TERIPARATIDE DISCONTINUATION – WHEN IS THE BEST TIME TO STARTING IT?" Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 836.2–837. http://dx.doi.org/10.1136/annrheumdis-2021-eular.2964.

Full text

Abstract:

Background:Treatment with teriparatide (TPTD) is associated with reduction of fracture risk in patients with severe osteoporosis. This drug can only be used for up to 2 years. After that a treatment course with antiresorptives should be considered, in order to prevent the rebound of bone turnover observed after TPTD discontinuation. In this regard, interest in sequential osteoporosis therapy has grown in recent years but the ideal timing for starting another treatment after TPTD is not well established.Objectives:The aim of this study is to assess if the timing of onset of antiresorptive thera

APA, Harvard, Vancouver, ISO, and other styles

27

Li, Joyce Tin Wing, and Yiu Yan Leung. "Effect of Antiresorptive Drugs on Osseointegrated Dental Implants: A Systematic Review." Journal of Clinical Medicine 13, no. 7 (2024): 2091. http://dx.doi.org/10.3390/jcm13072091.

Full text

Abstract:

Background: This systematic review aimed to evaluate the impact of antiresorptive drug therapy on osseointegrated dental implants and the association with medication-related osteonecrosis of the jaw (MRONJ). Methods: A systematic search, including a computer search of several databases with specific keywords, a reference search, and a manual search of four key maxillofacial journals were performed. Relevant articles were then evaluated and those that fulfilled the five predetermined criteria were chosen to enter the final review. A total of 445 implants in 135 subjects were included in the eig

APA, Harvard, Vancouver, ISO, and other styles

28

Malagrinò, Matteo, and Guido Zavatta. "Review of bone health in women with estrogen receptor–positive breast cancer receiving endocrine therapy." Women's Health 19 (January 2023): 174550572211494. http://dx.doi.org/10.1177/17455057221149493.

Full text

Abstract:

In estrogen-receptor-positive tumors, adjuvant endocrine therapy has been shown to be highly beneficial for both overall and disease-free survival. Estradiol is key in regulating bone and mineral physiology, and several studies found a strong correlation between these therapies and the risk of fractures. Since these therapies are often given for 5 through 10 years, the timing for bisphosphonates or denosumab initiation seems essential to managing bone metabolism. However, gray zones and discrepancies between guidelines remain as to the best threshold when to start antiresorptive treatment, or

APA, Harvard, Vancouver, ISO, and other styles

29

Kline, Gregory A., Suzanne N. Morin, Sidney Feldman, Lisa M. Lix, and William D. Leslie. "Diminishing Value from Multiple Serial Bone Densitometry in Women Receiving Antiresorptive Medication for Osteoporosis." Journal of Clinical Endocrinology & Metabolism 106, no. 9 (2021): 2718–25. http://dx.doi.org/10.1210/clinem/dgab211.

Full text

Abstract:

Abstract Context The value of serial bone mineral density (BMD) monitoring while on osteoporosis therapy is controversial. Objective We determined the percentage of women classified as suboptimal responders to therapy with antiresorptive medications according to 2 definitions of serial BMD change. Methods This was a cohort study using administrative databases at a single-payer government health system in Manitoba, Canada. Participants were postmenopausal women aged 40 years or older receiving antiresorptive medications and having 3 sequential BMD measures. Women stopping or switching therapies

APA, Harvard, Vancouver, ISO, and other styles

30

Vestergaard, Peter. "Antiresorptive Therapy for the Prevention of Postmenopausal Osteoporosis." Treatments in Endocrinology 4, no. 5 (2005): 263–77. http://dx.doi.org/10.2165/00024677-200504050-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Leah, Emma. "Future fracture factors—predicting failure of antiresorptive therapy." Nature Reviews Rheumatology 8, no. 2 (2012): 63. http://dx.doi.org/10.1038/nrrheum.2011.219.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Wark, J. "Antiresorptive therapy in bone disease: a physician's perspective." International Journal of Oral and Maxillofacial Surgery 44 (October 2015): e18. http://dx.doi.org/10.1016/j.ijom.2015.08.976.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Vargas-Hernández, Víctor Manuel. "BREAST CANCER AND BONE HEALTH UPTODATE." Archives of Gynaecology and Women Health 1, no. 1 (2023): 01–04. http://dx.doi.org/10.58489/2836-497x/005.

Full text

Abstract:

Background: breast cancer is the most common tumor in women worldwide and osteoporosis is linked to it, 70-80% of patients receive adjuvant endocrine therapy to improve prognosis; but, they accelerate bone loss and increase the risk of fractures by causing inflammation that stimulates bone breakdown and slows bone growth; Assessment of initial risk of fracture, monitoring of bone health and individualization based on initial risk, implementation of non-pharmacological measures, consideration of bone mineral density T-scores, guidance on criteria for starting antiresorptive treatment, choice of

APA, Harvard, Vancouver, ISO, and other styles

34

Anastasilakis, Athanasios D., Jessica Pepe, Nicola Napoli, et al. "Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS." Journal of Clinical Endocrinology & Metabolism 107, no. 5 (2021): 1441–60. http://dx.doi.org/10.1210/clinem/dgab888.

Full text

Abstract:

Abstract Context Antiresorptive therapy significantly reduces fracture risk in patients with benign bone disease and skeletal-related events (SREs) in patients with bone metastases (BM). Osteonecrosis of the jaw (ONJ) is a rare but severe condition manifested as necrotic bone lesion or lesions of the jaws. ONJ has been linked to the use of potent antiresorptive agents, termed medication-related ONJ (MRONJ). Objective We aimed to identify the differences various aspects of MRONJ among distinct patient categories and provide recommendations on how to mitigate the risk and optimally manage MRONJ

APA, Harvard, Vancouver, ISO, and other styles

35

Boonen, Steven, Fernando Marin, Barbara Obermayer-Pietsch, et al. "Effects of Previous Antiresorptive Therapy on the Bone Mineral Density Response to Two Years of Teriparatide Treatment in Postmenopausal Women with Osteoporosis." Journal of Clinical Endocrinology & Metabolism 93, no. 3 (2008): 852–60. http://dx.doi.org/10.1210/jc.2007-0711.

Full text

Abstract:

Abstract Introduction: EUROFORS was a 2-yr prospective, randomized trial of postmenopausal women with established osteoporosis, designed to investigate various sequential treatments after teriparatide 20 μg/d for 1 yr. The present secondary analysis examined the effects of 2 yr of open-label teriparatide in women previously treated with antiresorptive drugs for at least 1 yr. Methods: A subgroup of 245 women with osteoporosis who had 2 yr of teriparatide treatment were stratified by previous predominant antiresorptive treatment into four groups: alendronate (n = 107), risedronate (n = 59), eti

APA, Harvard, Vancouver, ISO, and other styles

36

Fleisher, Kenneth Evan, Franco Muggia, and Robert S. Glickman. "Medication-related osteonecrosis of the jaw: Evidence for infection versus oversuppression." Journal of Clinical Oncology 37, no. 15_suppl (2019): e18268-e18268. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e18268.

Full text

Abstract:

e18268 Background: Antiresorptive medications are important in maintaining bone health for patients with osteoporosis, metastatic cancer and multiple myeloma. Medication-related osteonecrosis of the jaw (MRONJ) may compromise quality of life and treatment of the underlying disease. There are many controversies regarding the pathogenesis, risk and management of MRONJ. Evidence-based data that suggest osteonecrosis of the jaw (ONJ) is triggered by infection and reports of ONJ unrelated to antiresorptive therapy (ART) have confounded previous hypotheses that pathogenesis is directly attributed to

APA, Harvard, Vancouver, ISO, and other styles

37

Tan, Juan, Hiroshige Sano, and Kenneth Poole. "Antiresorptive-associated spontaneous fractures of both tibiae, followed by an atypical femur fracture during the sequential treatment with alendronate, denosumab then teriparatide." BMJ Case Reports 12, no. 7 (2019): e229366. http://dx.doi.org/10.1136/bcr-2019-229366.

Full text

Abstract:

A 35-year-old man with juvenile idiopathic arthritis since childhood presented with bilateral atypical tibial fractures, followed by a later, single atypical fracture of the femur. The fractures were associated with 6 years of oral alendronate treatment immediately followed by subcutaneous denosumab therapy and later teriparatide therapy for osteoporosis. Atypical fractures are known to occur in the femur following bisphosphonate therapy; however, there are only a few documented cases of atypical fractures in the tibia. Our case highlights a rare but serious complication of a commonly prescrib

APA, Harvard, Vancouver, ISO, and other styles

38

Seeman, Ego. "S21 Alternatives to hormone replacement therapy: Antiresorptive therapy (bisphosphonates and calcitonin)." Maturitas 27 (November 1996): 29. http://dx.doi.org/10.1016/s0378-5122(97)80924-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Beaumont, Sophie, Simon Harrison, and Jeremy Er. "Review of Myeloma Therapies and Their Potential for Oral and Maxillofacial Side Effects." Cancers 13, no. 17 (2021): 4479. http://dx.doi.org/10.3390/cancers13174479.

Full text

Abstract:

Myeloma is a common haematological malignancy in which adverse skeletal related events are frequently seen. Over recent years, treatment for myeloma has evolved leading to improved survival. Antiresorptive therapy is an important adjunct therapy to reduce the risk of bone fractures and to improve the quality of life for myeloma patients; however, this has the potential for unwanted side effects in the oral cavity and maxillofacial region. Osteonecrosis of the jaw related to antiresorptive medications and other myeloma therapies is not uncommon. This review serves to highlight the risk of osteo

APA, Harvard, Vancouver, ISO, and other styles

40

Rückschloß, Thomas, Julius Moratin, Sven Zittel, et al. "Influence of Preventive Tooth Extractions on Quality of Life in Patients with Antiresorptive Intake—A Prospective Longitudinal Study." International Journal of Environmental Research and Public Health 18, no. 21 (2021): 11650. http://dx.doi.org/10.3390/ijerph182111650.

Full text

Abstract:

Background: To find out whether preventive tooth extractions in patients on antiresorptive therapy have a direct impact on the patients’ overall quality of life (QoL); Methods: QoL using the five-level version of the EuroQol Group’s EQ-5D instrument (EQ-5D-5L) was longitudinally assessed in N = 114 prospectively enrolled patients with indication of preventive tooth extraction over a period of 12 months. Patients were stratified as high-risk (malignant disease with bone metastasis or multiple myeloma, with monthly high-dose antiresorptive therapy delivered intravenously [bisphosphonate] or subc

APA, Harvard, Vancouver, ISO, and other styles

41

Khan, Aliya A., William D. Leslie, Brian Lentle, et al. "Atypical Femoral Fractures: A Teaching Perspective." Canadian Association of Radiologists Journal 66, no. 2 (2015): 102–7. http://dx.doi.org/10.1016/j.carj.2014.01.002.

Full text

Abstract:

This article provides an overview of atypical femoral fractures with a highlight on their radiographic findings. Potent antiresorptive agents such as bisphosphonates or denosumab have been associated with the development of such fractures. However, at this time, a causal association has not been conclusively established. Atypical femoral fractures are insufficiency fractures, which frequently present with bone pain. Early identification of characteristic radiographic features and withdrawal of antiresorptive therapy may prevent the development of completed atypical femoral fractures.

APA, Harvard, Vancouver, ISO, and other styles

42

Yamamoto, Shinsuke, Keigo Maeda, Izumi Kouchi, et al. "Development of Antiresorptive Agent-Related Osteonecrosis of the Jaw After Dental Implant Removal: A Case Report." Journal of Oral Implantology 44, no. 5 (2018): 359–64. http://dx.doi.org/10.1563/aaid-joi-d-18-00032.

Full text

Abstract:

Dental implant treatment is a highly predictable therapy, but when potentially lethal symptoms or complications occur, dentists must remove the implant fixture. Recently, reports on antiresorptive agent-related osteonecrosis of the jaw have increased in the field of dental implants, although the relationship between dental implant treatment and antiresorptive agents remains unclear. Here, we report a case of antiresorptive agent-related osteonecrosis of the jaw that developed after dental implant removal. A 67-year-old Japanese woman with a medical history of osteoporosis and 7 years of oral b

APA, Harvard, Vancouver, ISO, and other styles

43

Favia, Gianfranco, Angela Tempesta, Luisa Limongelli, Vito Crincoli, and Eugenio Maiorano. "Medication-Related Osteonecrosis of the Jaws: Considerations on a New Antiresorptive Therapy (Denosumab) and Treatment Outcome after a 13-Year Experience." International Journal of Dentistry 2016 (2016): 1–9. http://dx.doi.org/10.1155/2016/1801676.

Full text

Abstract:

Medication-related osteonecrosis of the jaw (MRONJ) is a serious complication in patients receiving antiresorptive therapies for bone neoplastic localizations and osteoporosis. The aim of this study was to evaluate the clinicopathological features of MRONJ in a cohort of patients treated by new antiresorptive drugs (denosumab) and the corresponding outcome after 13-year maximum follow-up. Overall, 244 patients affected by MRONJ were treated from 2003 to 2015. After clinical and radiological examinations, all lesions were staged according to a dimensional staging system and then surgically trea

APA, Harvard, Vancouver, ISO, and other styles

44

Spevak, Elena, Dmitry Christoforando, Grigoriy Sazanov, and Anna Cymbal. "DEVELOPMENT OF INFORMED VOLUNTARY CONSENT FOR VARIOUS TYPES OF DENTAL INTERVENTIONS FOR PATIENTS TAKING ANTIRESORPTIVE DRUGS." Actual problems in dentistry 17, no. 4 (2022): 151–57. http://dx.doi.org/10.18481/2077-7566-21-17-4-151-157.

Full text

Abstract:

Subject. The number of patients taking antiresorptive drugs (bisphosphonates and denosumab) is steadily increasing. The need of this group of patients for dental care continues to be high. In this regard, the prevalence of complications of antiresorptive therapy – drug osteonecrosis of the jaws – tends to increase. Therefore, the problem of awareness of doctors and patients on the assessment of the risk of drug osteonecrosis of the jaws and its prevention is of high relevance.  The aim of the study is to develop a form of informed voluntary consent for types of dental interventions for p

APA, Harvard, Vancouver, ISO, and other styles

45

Amar, Inbal Dona, Gianluca Franceschini, Camilla Nero, et al. "Preventing Bone Loss in Breast Cancer Patients: Designing a Personalized Clinical Pathway in a Large-Volume Research Hospital." Journal of Personalized Medicine 14, no. 4 (2024): 371. http://dx.doi.org/10.3390/jpm14040371.

Full text

Abstract:

Background: We assess the impact of bone health clinical management in breast cancer (BC) patients receiving adjuvant endocrine therapy and design a personalized clinical pathway to reduce bone loss in an Italian research hospital. Methods: The primary endpoint was to assess (through the process improvement organizational method) the clinical pathway that post-surgical BC patients prescribed with endocrine therapy undergo to prevent bone loss. The secondary endpoint was to design a personalized clinical pathway for a prompt implementation of guidelines, to assess and possibly prescribe antires

APA, Harvard, Vancouver, ISO, and other styles

46

AlOmran, Abdullah S. "Osteoporosis-Related Simultaneous Four Joints Fractures and Dislocation after a Seizure: A Case Report." Journal of Osteoporosis 2010 (2010): 1–4. http://dx.doi.org/10.4061/2010/808341.

Full text

Abstract:

A case of steroid-induced osteoporosis-related multiple fractures and dislocations are described after a seizure is reported. Patient had two years history of steroid use with no supplement or antiresorptive therapy. There was a delay in the diagnosis which affected an otherwise good outcome in such situations. It is recommended that patients on steroid should be given calcium, vitamin D, and an antiresorptive. Furthermore, a meticulous clinical examination is required in patients who are on steroids and suffer epileptic seizures to rule out skeletal injury.

APA, Harvard, Vancouver, ISO, and other styles

47

Supanumpar, Nachapol, Pagaporn Pantuwadee Pisarnturakit, Natthinee Charatcharoenwitthaya, and Keskanya Subbalekha. "Physicians’ awareness of medication-related osteonecrosis of the jaw in patients with osteoporosis." PLOS ONE 19, no. 1 (2024): e0297500. http://dx.doi.org/10.1371/journal.pone.0297500.

Full text

Abstract:

A serious adverse effect of antiresorptive drugs, which are widely used to treat osteoporosis, is medication-related osteonecrosis of the jaw (MRONJ). Physicians can reduce the risk of MRONJ by educating patients and emphasizing the importance of good oral health. However, limited information is available regarding physicians’ awareness and clinical practices associated with MRONJ. Hence, this study aimed to examine physicians’ awareness related to MRONJ and associated clinical practices. This study was a cross-sectional study conducted from December 2022 to February 2023. An online self-admin

APA, Harvard, Vancouver, ISO, and other styles

48

Fassio, A., F. Bertoldo, L. Idolazzi, O. Viapiana, M. Rossini, and D. Gatti. "Drug-induced osteonecrosis of the jaw: the state of the art." Reumatismo 69, no. 1 (2017): 9. http://dx.doi.org/10.4081/reumatismo.2017.983.

Full text

Abstract:

Osteonecrosis of the jaw (ONJ) is a rare adverse event of antiresorptive drugs such as bisphosphonates (BP) and denosumab (DMAb). The diagnosis of ONJ is considered in cases where exposed bone in the maxillofacial region does not heal within 8 weeks in a patient previously treated with an antiresorptive agent. In patients with osteoporosis, ONJ is reported as a very rare adverse event while in oncologic patients with bone metastases or malignant hypercalcemia the incidence is significantly higher (up to the 1-10% of the patients). The pathophysiology of ONJ is still not completely understood b

APA, Harvard, Vancouver, ISO, and other styles

49

Lobanova, K. G., and F. O. Ushanova. "Diagnosis and treatment of osteoporosis: a paradigm shift." FOCUS. Endocrinology 5, no. 1 (2024): 65–73. http://dx.doi.org/10.62751/2713-0177-2024-5-1-09.

Full text

Abstract:

The main clinical manifestation of osteoporosis is a low-energy fracture. Fracture is associated with a high risk of disability and mortality. Therefore, the aim of osteoporosis treatment is to reduce the risk of fractures. Therefore, experts from the UK in 2019 developed and put into practice a fracture risk stratification system, on the basis of which a decision is made on the treatment of patients with osteoporosis. So patients with a very high risk of fractures need to prescribe anabolic therapy, followed by the appointment of antiresorptive drugs. Patients at high risk – the appointment o

APA, Harvard, Vancouver, ISO, and other styles

50

Koth, Valesca Sander, Dieni Da Silveira Teixeira, Éverton Adriano Wegner, et al. "ALVEOLAR HEALING OF TOOTH EXTRACTION UNDER ORAL ANTIRESORPTIVE THERAPY." Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 134, no. 3 (2022): e221. http://dx.doi.org/10.1016/j.oooo.2022.01.698.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!